ZURICH (Reuters) – Relief Therapeutics said on Wednesday it and U.S. partner NeuroRx asked the U.S. Food and Drug Administration for emergency approval for a drug it aims to repurpose against COVID-19, citing a 51-person study the Swiss drugmaker said showed the medicine helped sick patients.
“Patients treated with RLF-100 demonstrated a 3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement,” the company said in a statement, adding the request, if granted, would make the drug — previously used against conditions including erectile dysfunction — available to those in intensive care who have exhausted all approved treatments.
(Reporting by John Miller; Editing by Michael Shields)
